DOCSLIB.ORG

Generic Total Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Generic Total Drug List Generic Drugs Sr. No. Drug code Generic name of the drug 1 1 Aceclofenac 100mg and Paracetamol 325mg Tablet 2 2 Aceclofenac Tablets IP 100mg 3 3 Pregabalin Capsules IP 75mg 4 4 Acetaminophen 325mg + Tramadol Hydrochloride 37.5mg Film Coated Tablet 5 5 ASPIRIN Tablets IP 150 mg 6 6 Diclofenac 50 Mg+ Paracetamol 325 Mg+ Chlorzoxazone 500 Mg Tablets 7 7 Diclofenac Gel BP (Diclofenac Diethylamine 1.16%w/w) 8 8 Diclofenac Sodium 50Mg + Serratiopeptidase 10Mg Tablet 9 9 Diclofenac Prolonged Release Tablet 100 Mg 10 10 Diclofenac Sodium 25mg per ml Inj. IP 11 11 Diclofenac Gastro-Resistant Tablets IP 50 Mg 12 12 Etoricoxib Tablets IP 120Mg 13 13 Etoricoxib Tablets IP 90Mg 14 14 Ibuprofen 400 Mg + Paracetamol 325 Mg Tablets IP 15 15 Ibuprofen 200 Mg Film Coated Tablet IP 16 16 Ibuprofen 400 Mg Film Coated Tablet IP 17 20 Nimesulide Bp 100 Mg Tablets 18 21 Diclofenac Sodium 50 Mg And Paracetamol 325 Mg Tablets IP 19 22 Paracetamol Suspension IP 125Mg/5Ml 20 23 Paracetamol Tablets IP 500Mg 21 24 Pentazocine Injection IP 30mg/ml 22 25 Serratiopeptidase Tablets IP 10 Mg 23 26 Tramadol Hcl 100 Mg Injection 24 27 Tramadol Hcl Injection 50Mg 1Ml 25 28 Tramadol 50 Mg Tablet 26 29 Acyclovir 400mg Tablets 27 30 Amikacin Injection IP 100Mg/2Ml 28 31 Amikacin Injections IP 250Mg 29 32 Amikacin Injections IP 250Mg/Ml 2Ml 30 33 Metformin Hydrochloride Prolonged Release 500 Mg And Glimepiride 2 Mg Tablets IP 31 34 Metformin Hcl 500 Mg Pr And Glimepiride 2 Mg Tablets IP 32 Amoxycillin 1000 Mg And Potassium 35 Clavulanate (Clavulanic Acid 200Mg) Injection IP 33 Amoxycillin 200 Mg, Potassium Clavulanate (Clavulanic Acid 36 28.5Mg) Per 5Ml Oral Suspension 34 37 Amoxycillin 250mg + Clavulanic acid 50 mg Inj. 35 Amoxycillin 500Mg + Potassium Clavulanate (Clavulanic Acid 38 100Mg) Injection 36 39 Amoxycillin 500mg + Clavulanic acid 125 mg film coated Tablet 37 40 Amoxycillin 250Mg + Cloxacillin 250 Mg Capsules 38 42 Amoxycillin Dispersible Tablets IP 125 Mg 39 43 Amoxycillin 125Mg/ 5Ml Dry Syrup 40 44 Amoxycillin Capsules IP 250Mg 41 45 Amoxycillin Capsules IP 500Mg 42 47 Azithromycin Oral Suspension 100 Mg/5Ml 43 48 Azithromycin 100 Mg Dispersible Tablet 44 49 Azithromycin 250 Mg Film Coated Tablet IP 45 50 Azithromycin 500 Mg Film Coated Tablet IP 46 51 Cefadroxil Dispersible Tablets 250Mg 47 52 Cefadroxil 500Mg Film Coated Tablet IP 48 53 Cefixime Oral Suspension IP 50Mg/5Ml 49 54 Cefixime Film Coated Tablets IP 100Mg 50 55 Cefixime Film Coated Tablets IP 200Mg 51 56 Cefoperazone 1Gm + Sulbactam 1Gm Injection 52 57 Cefoperazone 500Mg+ Sulbactam 500 Mg Injection 53 58 Cefoperazone Injection IP 1gm 54 Cefotaxime Sodium 1 Gm+ Sulbactam Sodium 500 Mg Injection 59 55 62 Cefotaxime Sodium 1000Mg Injection IP 56 63 Cefotaxime Sodium 250 Mg Injection IP 57 64 Cefotaxime Sodium 500 Mg Injection IP 58 65 Cefpodoxime Proxetil 100 Mg Dispersible Tablet IP 59 66 Cefpodoxime Film Coated Tablets IP 200Mg 60 67 Ceftazadime Injection IP 1000 Mg 61 68 Ceftazadime Injection IP 250 Mg 62 69 Ceftazadime 500 mg Inj. 63 70 Ceftriaxone 1000mg+ Sulbactam 500 mg Inj. 64 71 Ceftriaxone 1000Mg + Tazobactum 125 Mg Injection. 65 73 Ceftriaxone 250 Mg + Sulbactum 125 Mg Injection With Wfi 66 74 Ceftriaxone 500mg with Sulbactum 250mg Injection 67 75 Ceftriaxone Injection IP 1g 68 76 Ceftriaxone 250 mg Inj. 69 77 Ceftriaxone 500 mg Inj. 70 78 Cefuroxime Axetil 250 Mg Film Coated Tablets IP 71 79 Cefuroxime Axetil 500Mg Film Coated Tablet IP 72 80 Cephalexin Dispersible Tablets 125Mg 73 81 Cephalexin Capsules IP 250Mg 74 82 Cephalexin Capsules IP 500Mg 75 Ciprofloxacin 250Mg + Tinidazole 300Mg Film Coated Tablet 83 76 Ciprofloxacin 500Mg + Tinidazole 600Mg Film Coated Tablet 84 77 85 Ciprofloxacin 250 Mg Film Coated Tablet IP 78 86 Ciprofloxacin 500 Mg Film Coated Tablet IP 79 87 Clotrimazole 1% W/W Cream 80 92 Doxycycline Capsules IP 100Mg 81 93 Erythromycin Stearate 250 mg film coated Tablet 82 94 Gentamycin Sulphate 80 mg/ 2ml Inj. 83 95 Levofloxacin Film Coated Tablets IP 250Mg 84 96 Levofloxacin Film Coated Tablets IP 500Mg 85 97 Meropenem Injection IP 1G 86 Norfloxacin 400 Mg + Tinidazole 600 Mg Film Coated Tablet 98 87 99 Norfloxacin 400 Mg Film Coated Tablets IP 88 100 Ofloxacin 200 Mg + Ornidazole 500 Mg Film Coated Tablet 89 101 Ofloxacin Film Coated Tablets IP 200Mg 90 102 Ofloxacin Tablets IP 400 Mg Film Coated 91 103 Piperacillin 4Gm + Tazobactum 0.5 Gm Injection IP 92 107 Tinidazole 300 Mg Film Coated Tablets IP 93 108 Tinidazole Film Coated Tablets IP 500Mg 94 109 Vancomycin Injection IP 500 Mg 95 110 Adapalene 0.1%W/V Ointment 96 Beclomethasone DIPropionate IP 0.025 % W/W ,Clotrimazole IP 1 112 % W/W , Gentamycin Sulphate 0.1 % W/W 97 113 Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream 98 115 Calamine Lotion IP 99 117 Chlorhexidine Mouthwash IP 0.2 % W/V 100 118 Clobetasol Propionate 0.05 % w/w Cream 101 119 Fluconazole Tablets IP 150 Mg Film Coated 102 120 Fusidic Acid Cream 2%w/w 103 122 Ketoconazole 2% W/W Lotion 104 124 Povidone Iodine 5% w/w Ointment USP 105 125 Povidone Iodine 5%W/W Ointment 106 126 Povidone Iodine 10 % Solution 107 127 Povidone Iodine 5 % Solution IP 108 128 Povidone Iodine 5% Solution 500 ML 109 129 Povidone Iodine 7.5% Solution 110 133 Glibenclamide 2.5 Mg Tablet IP (Scored Oval) 111 134 Glibenclamide 5 Mg Tablets IP (Scored Oval) 112 135 Gliclazide 40 Mg Tablets IP 113 136 Gliclazide 80 Mg Tablets IP 114 137 Glimeperide Tablets IP 1Mg 115 138 Glimeperide Tablets IP 2Mg 116 141 Glipizide 5 Mg Tablet IP 117 142 Insulin Injection IP 40 Iu/Ml (Insulin Human Recombinant) 118 Insulin Injection (Insulin Human Soluble 30% & Isophane 70%) 40 143 Iu/Ml 119 144 Metformin Hydrochloride 1000 Mg Sr Tablets IP 120 145 Metformin Hydrochloride Tablets IP 500Mg 121 146 Pioglitazone 15 Mg Tablets IP 122 147 Pioglitazone 30 Mg Tablets IP 123 150 Metformin 500Mg Sr +Pioglitazone 15Mg Tablet IP 124 155 Doxorubicin Injection IP 10 Mg 125 156 Doxorubicin Injection IP 50Mg 126 163 Tamoxifen Citrate 10 Mg I.P Tablets 127 164 Tamoxifen Citrate 20 Mg I.P Tablets 128 165 Ciprofloxacin (2mg/ml) Infusion 129 169 Levofloxacin 500Mg I.P Infusion 130 170 Mannitol Injections IP 20%w/v 131 172 Metronidazole 5 mg / ml Infusion 132 176 Sterile Water for Injection 133 177 Albendazole Suspension IP 200 Mg/ 5Ml 134 178 Albendazole 400Mg + Ivermectin 6Mg Tablets 135 179 Albendazole Tablets IP 400Mg 136 180 Bisacodyl Tablets IP 5Mg 137 TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml 181 SYRUP 138 183 Dicyclomine Tablets IP 10Mg 139 184 Paracetamol 325 Mg And Dicyclomine Hcl 20 Mg Tablet 140 185 Diethylcarbamazine citrate 100mg film coated Tablets 141 186 Domperidone 10 Mg I.P Tablet 142 187 Domperidone 5 Mg. / 5 Ml I.P Suspension 143 Aluminium Hydroxide +Mg. Hydroxide+ Act. Dimethicone (250mg 188 +250mg+50mg)Tablets 144 191 Famotidine 20 Mg I.P Tablet 145 192 Famotidine 40 Mg I.P Tablet 146 193 Furazolidone IP 100 Mg Tablet 147 194 Hyoscine Butyl Bromide 10 Mg Film Coated Tablet 148 195 Isapgol Husk 200Gm IP 99% 149 196 Lactobacillus Sporogenes 60 Million Spores Tablets 150 197 Lactulose 10 g/15 ml Syrup 151 Dried Aluminium Hydroxide IP 250Mg, Magnesium Hydroxide IP 198 250Mg, Activated Methyl Polysiloxane 50/5Ml Syrup 152 199 Metoclopramide 10 Mg I.P Tablets 153 200 Metoclopramide Injection IP 5Mg/Ml 154 201 Metronidazole Film Coated Tablets IP 200Mg 155 202 Metronidazole Film Coated Tablets IP 400Mg 156 203 Misoprostol 200 mcg film coated Tablet 157 206 Omeprazole 20Mg + Domperidone 10 Mg I.P Capsules 158 207 Omeprazole 20 Mg I.P Capsules 159 208 Ondansetron 2 Mg/Ml I.P Injection 160 209 Ondansitron Tablets IP 4Mg 161 210 Ornidazole Film Coated Tablets IP 500Mg 162 212 Pantoprazole Enteric Coated Tablets IP 40Mg 163 213 Pantoprazole Injection IP 40Mg 164 214 Rabeprazole 20 Mg And Domperidone Sr 30 Mg Capsule 165 215 Rabeprazole Gastro-Resistant Tablets IP 20Mg 166 216 Ranitidine (50 Mg/ 2Ml) Injection 167 217 Ranitidine Hcl Tablet IP 150 Mg Film Coated 168 218 Ranitidine Hcl Tablets IP 300 Mg Film Coated 169 Calcium Carbonate 1250Mg (Calcium 500Mg) + Vitamin D3 250 220 Iu Film Coated Tablet 170 PYRIDOXINE HCl 10 mg+ DOXYLAMINE 10 mg + FOLIC ACID 2.5 mg 223 Tablets 171 224 Folic Acid Tablets IP 5Mg 172 Iron And Folic Acid (Elemental Iron 30Mg + Folic Acid 0.5Mg) 225 Flavoured Base Syrup 173 Iron (Carbonil Iron) 100Mg + Folic Acid 1.5 Mg + Zinc Capsules 226 174 227 Polyvitamin (Prophylactic) NFI 175 229 Haematinic Syrup Of Iron,Folic Acid And Vitamin B12 176 Vitamin B-Complex (B1,B2,B6,B12) & Vitamin 'C' With Zinc 230 22.5Mg Capsule 177 Vitamin B1 10Mg, B2 10Mg, B3 45Mg, B5 50Mg, B6 3Mg, B12 231 15Mcg Tablets 178 233 Vitamin-C Chewable 500Mg Tablet 179 235 Budesonide Respules 0.5Mg/Ml 180 236 Budesonide 100 mcg/dose Inhaler 181 238 Budesonide 200 mcg/dose Inhaler 182 239 Cetirizine (5 Mg/ 5 Ml) I.P Syrup 183 240 Cetrizine Tablet IP 10Mg Film Coated 184 Cough Syrup DIPhenhydramine 14 Mg + Ammonium Chloride 135 243 Mg+ Sodium Citrate 57 Mg + Menthol IP 0.9 Mg 185 244 Etophyllin and Theophylline Inj. (84.7mg+25.3 mg) mg/2ml 186 246 Fexofenadine 120Mg Film Coated Tablet 187 247 Fexofenadine 180Mg Film Coated Tablet 188 248 Levocetrizine Film Coated Tablets IP 5Mg 189 250 Montelukast Sodium Tablets IP 5Mg 190 251 Montelukast Sodium Tablets IP 10Mg 191 Levocetrizine 5Mg And Montelukast Sodium 10Mg I.P Film Coated 252 Tablet 192 253 Pheniramine Maleate 25 mg 193 254 Promethazine (5mg/5ml) syrup 194 255 Salbutamol 100 mcg/puff Inhaler 195 256 Salbutamol Tablets IP 2Mg 196 259 Salbutamol 2Mg /5Ml I.P Syrup 197 260 Salbutamol 4 Mg I.P Tablets 198 263 AmlodIPine 5Mg And Atenolol 50Mg Tablet 199 264 AmlodIPine Tablets IP 5Mg 200 265 Atenolol Tablets IP 50 Mg 201 266 Atorvastatin 10Mg Film Coated Tablet IP 202 267 Atorvastatin Film Coated Tablets IP 20Mg 203 268 Clonidine 0.1 mg Tabs 204 269 Clopidogrel Tablets IP 75Mg 205 270 Aspirin 75 Mg + Clopidogrel 75 Mg Tablets 206 271 Diltiazem 30 Mg I.P Tablets 207 272 Diltiazem 60Mg I.P Tablets 208 273 Dobutamine Injection IP 250mg/20ml 209 274 Dopamine HCl 200 mg/5ml Inj.
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
    [Show full text]
  • Oxaceprol Monotherapy Versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis
    Original Article ISSN (Print) : 2454-8952 International Journal of Medical and Dental Sciences, Vol 9(2), DOI: 10.18311/ijmds/2020/24871, July 2020 ISSN (Online) : 2320-1118 Oxaceprol Monotherapy versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis Vijay Kumar1, Sanjeev Sareen2, Shrey Bhatia3* 1Professor and Head, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India 2Associate Professor, Department of Orthopaedics, Government Medical College, Patiala – 147001, Punjab, India 3Junior Resident, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India; [email protected] Abstract Introduction: Osteoarthritis (OA) is the commonest form of arthritis which presents with joint pain and functional limitations. Oxaceprol, a derivative of hydroxyproline, inhibits leukocyte migration into the joints thus inhibiting Proline in chondrocytes. Aims and Objective: Glucosamineinflammatory combination process. Oxaceprol therapy also in patients increases diagnosed availability with of Knee Glucosamine Osteoarthritis and improving (KOA). Materials uptake ofand Glucosamine Methods: Thisand To demonstrate efficacy of Oxaceprol Monotherapy versus Oxaceprol and randomly received either Oxaceprol 600mg OD for 4 weeks, or combination of Oxaceprol 600mg OD and Glucosamine was an open labelled, parallel group, Randomized Controlled Trial where 40 adults age ≥50 years diagnosed with KOA visual analogue scale (VAS) recording from baseline to 4 weeks of treatment. Results: Our study showed that both Oxaceprol monotherapySulphate 1500mg (group OD A, for n=20), 4 weeks. and GlucosamineThe patients pluswere Oxaceprol analysed ascombination per the differences therapy (group between B, n=20) WOMAC improved scale scores, joint pain, and stiffness, and functionality as shown by analysing WOMAC scores before, and after 4 weeks of treatment.
    [Show full text]
  • La. ADMINISTRATION of DAMAN & DIU OFFICE of the HEAD of OFFICE/HEALTH OFFICER GOVERNMENT HOSPITAL, DIU (362 520)
    iiv utsr T;3Tvr V ifta UTrTT Farf% T 3r d (Z9't 3r-4c Tom) WT 4114C414, i TWt 3TF9c1I i, i la-362520. ir. ii3r41/ii T/1(2)/1 -20/2016-2017/301. fka* :- 02/08/2016. *-fr Wr3W) SMi T i ' i 'i11 * AT * ialft r Citct']^1 q T-^r&T (iriq+rf1 379ciis), ,1"d q, F71Ftq * , , U)' UM 79 M-401 3rt9'Trci, t a 4 111AIREF, Tc 'lr1 Lrd *U u hC iit rl *t 3TiV i f^lv ft &M WiiW W04cii3T1icn1b cr $1cci1/3rrqpV^ft34 i1 http_//daman.nprocure.com qi 3i- T fWf T 3Trr 9 I f1T 7W www. daman.nic.in qi 3ft < 6 t I WA i41j1f4 #f WT fur 3T ;5r7 T Tft (ftwfg fir N1i Ic i * Tr ) (3i,i1 ) 2. 3. 4. 01. iii T1Zp Fszi Er11 r Lrcr iri^rtl T. 4,50,000/- T. 2,000/- 3rF^-T1 cam, i a ' fv "'A iii V r c iff *+ is1$d 3T1- T T 1 f t ZR 4,A 3i3 c S WE# *t 3rfc r M ft :- 23/08/2016 41 12.00 Wi1 ^W. 3 i r a - l T 3 1 f r i tc I .,i V 9 1 t *r 3i1 err :- 23/08/2016 ;E^t 13.00 a4 -TW. Ar r ft 3ird-c i:T i)W# *t itrr :- 1 mm T3Tr t 23/ 08/2016 ;E^t 16.00 W4. f l ih1 -sir ift cr if s u1Tq 4 www.nprocure.com W{ 3rfc'IJR arilzrr T iRm i vf^ff v i i t m e1Jrr I vi^w ft ftDqpj AiTq i f! S # 1 fPjf^r # Fi Ti Tf f f + Tr i TVIU I f'df i S r &A.
    [Show full text]
  • Diclofenac in the Treatment of Pain in Patients with Rheumatic Diseases
    Review paper Reumatologia 2018; 56, 3: 174–183 DOI: https://doi.org/10.5114/reum.2018.76816 Diclofenac in the treatment of pain in patients with rheumatic diseases Justyna Kołodziejska, Michał Kołodziejczyk Department of Pharmaceutical Technology, Chair of Applied Pharmacy, Medical University of Lodz, Poland Abstract Diclofenac, a phenylacetic acid derivative, is a drug demonstrating high efficacy after oral adminis- tration in the treatment of pain and physical disability in rheumatic diseases. In view of the adverse effects associated with using diclofenac, it is necessary to consider all known drug safety informa- tion before the drug is selected for therapy and the dosage regimen is set for individual patients. Selecting an oral dosage form with specific properties determined by excipients is a method to im- prove the availability of the drug substance and, at the same time, minimize adverse drug reactions. An alternative to tablet or capsule dosage forms is diclofenac application to the skin. The proven efficacy of this method is further improved through the use of transdermal penetration enhancers and vehicle ingredients which provide dosage forms with specific physical properties. Key words: diclofenac, efficacy, adverse effects, dosage form technology. Introduction on the market also exhibit technological differences (dosage form modifications). Intense pharmacological Diseases of the musculo-skeletal system affect 70% and formulation research is currently being conducted of the population over the age of 50 years. Pain caused to obtain more effective and safer products [2]. by rheumatic diseases decreases or resolves during re- NSAIDs are effective in multiple indications. In rheu- mission-inducing treatment. Drugs used in the therapy matology, they are used in the treatment of a range of of rheumatic diseases usually have a late onset of ac- diseases including rheumatoid arthritis, lupus erythe- tion.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Attachment 9.Pdf
    Kyowa Hakko U.S.A., Inc. Dated: February 14, 2003 N-Acetyl-L-Hydroxyproline New Dietary Ingredient Notification Reference No. 9 ? Clin Rheumatol (2000) 19:99-104 0 2000 Clinical Rheulnatology Clinical Rheumatology Original Article Oxaceprol is a Well-Tolerated Therapy for Osteoarthritis with Efficacy Equivalent to Diclofenac G. Herrmann’, D. Steeger’, M. Klasser*, J. Wirbitzky’, M. Fiirst4, R. Venbrocks’, H. Rohde6, D. Jungmiche17, H. D. Hildebrandt’, M. J. Parnham9, W. Gimbell’ and H. Dirschedl’ ‘BayerischesRotes Kreuz, Orthop&discheKlinik Lindenlohe,Schwandorf; ‘Gesellschaft fur wissenschaftlicheDatenverarbeitung + Didaktik mbH, MiihlheimiMain; 3Kurpark-Klinik,Bad Schussenried;4Schlo13park-Kliniken, Bad Waldsee;‘ Orthopgdische Uniklinik am Rudolf-Elle-Krankenhaus,Eisenberg; 6Fachklinikfiir Orthopadieund Rheumatologie,Oberstdorf; 7Fachklinik fir Orthopadie,Bad Dfiben; ‘Klinik am Homberg,Bad Wildungen;“ PamhamAdvisory Services,Bonn; and “ChephasaarGmbH, St Ingbert, Germany Abstract: The therapeutic equivalence and safety of was statistically significant (p = 0.04106) for the number treatment for 21 days with 400 mg t.i.d. oxaceprol (n = of these adverse events. Oxaceprol is therapeutically 132) and 50 mg t.i.d. diclofenac (n = 131) were assessed equivalent to diclofenac, but better tolerated than in a multicentre, randomised, double-blind study of a diclofenac in the treatment of osteoarthritis. mixed population of patients with osteoarthritis of the knee and/or hip. In a per-protocol analysis of efficacy, Keywords: Diclofenac; Lequesne index; Osteoarthritis; the mean Lequesne index decreasedby 2.5 points in the Oxaceprol; Pain oxaceprol group (n = 109) and by 2.8 points in the diclofenac group (n = 109). The 95% confidence interval for the end-point difference revealed therapeutic equivalence. This was confirmed by assessments (visual analogue scale) of pain at rest, weight-bearing pain, pain on standing and pain on movement, all of Introduction which decreased to a similar extent under both treatments.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Obesity Invites Osteo-Arthritis in Young Women Weight Reduction Be the Main Stay of Management! a Case Study
    5 ISSN: 2687-816X DOI: 10.33552/GJOR.2021.03.000565 Global Journal of Orthopedics Research Research Article Copyright © All rights are reserved by S Tejesh Obesity Invites Osteo-Arthritis in Young Women Weight Reduction be the Main Stay of Management! A Case Study S Tejesh1* and Suresh Kishanrao2 1 S Tejesh MPH, School of Public Health & Environmental Sciences, Karnataka state rural development and panchayat raj university Gadag, India 2 Suresh Kishanrao, Public Health Consultant and Vissiting Professor, MPH, School of Public Health & Environmental Sciences, KSRDPRU, Gadag, India *Corresponding author: S Tejesh, MPH, School of Public Health & Environmental Received Date: July 26, 2021 Sciences, Karnataka state rural development and panchayat raj university Gadag, India. Published Date: August 18, 2021 Abstract Knee osteoarthritis (OA), also known as degenerative joint disease of the knee, is typically the result of wear and tear and progressive loss of articular cartilage. Age, weight and gender are the predisposing risk factors and symptoms are swelling, pain and stiffness at knee joint. We here present a case of 43-year-old housewife reported with pain, swelling and stiffness at right knee on 5 May 2021 was taken to nearby orthopedician. After physical examination and radiological investigation, she was diagnosed with knee osteoarthritis. He treated her with some analgesics and anti-inflammatory drugs and suggested to take physical therapy and counselled for weight reduction. In a follow up visit she had reduced her weight byBackground 3 kgs in a month’s time and was doing fine. We infer that weight of an individual plays an important role in the incidence of knee osteoarthritis.
    [Show full text]